Gentibio

Company Type: Therapeutic development

Main focus: Advancing engineered regulatory T cells (Tregs) therapies to treat various diseases

Company stage: Pre-clinical

Diseases: Type 1 diabetes and other autoimmune and autoinflammatory disease

Genome-editing tool: Homology-directed repair–based (HDR-based) genome editing

Funding stage: Series A

Location: Seattle, Washington, United States

Website: https://www.gentibio.com/

Pipeline: www.gentibio.com/pipeline-programs/our-pipeline/

Partners:

Gentibio is a biotechnology company focused on advancing the use of autologous regulatory T cells (Tregs) to treat human disease. Gentibio’s scientific approach involves gene editing regulatory T (Treg) cells to produce engineered Treg therapies that can suppress inflammation and autoimmune dysfunction in a tissue-restricted manner. The platform uses homology-directed repair-based gene editing to express FOXP3 among other edits. The company's most advanced candidate GNTI-122 is developed using CRISPR-Cas0 gene editing, and has shown promising pre-clinical results in treating type 1 diabetes.